Dawson James analyst Jason Kolbert reiterated a Buy rating on ADiTx Therapeutics Inc. (NASDAQ: ADTX).The analyst comments: "Our valuation for ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE